Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes
| Autor: | M J Thomason, Helen M. Colhoun, Graham A. Hitman, Mike Mackness, Cards Investigators, H. A. W. Neil, D. J. Betteridge, P.N. Durrington, Shona Livingstone, J. H. Fuller |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Randomization Endocrinology Diabetes and Metabolism Atorvastatin Coronary Disease Type 2 diabetes Diabetic angiopathy law.invention Endocrinology Randomized controlled trial law Internal medicine Diabetes mellitus Internal Medicine Humans Medicine Pyrroles Stroke Triglycerides Aged business.industry Anticholesteremic Agents Cholesterol HDL Cholesterol LDL Middle Aged medicine.disease Surgery Diabetes Mellitus Type 2 Heptanoic Acids Female lipids (amino acids peptides and proteins) business Diabetic Angiopathies medicine.drug Retinopathy |
| Zdroj: | Diabetic Medicine. 21:901-905 |
| ISSN: | 1464-5491 0742-3071 |
| DOI: | 10.1111/j.1464-5491.2004.01401.x |
| Popis: | AIM: To describe baseline characteristics of patients in the Collaborative AtoRvastatin Diabetes Study (CARDS), a randomized, placebo-controlled trial of lipid lowering with atorvastatin 10 mg daily for the primary prevention of major cardiovascular events in patients with Type 2 diabetes. METHODS: The main eligibility criteria were Type 2 diabetes, age 40-75 years, no previous history of coronary heart disease, stroke or other major cardiovascular events, a documented history of at least one of retinopathy, micro- or macroalbuminuria, hypertension or current smoking, LDL-cholesterol < or = 4.14 mmol/l and triglycerides < or = 6.78 mmol/l. RESULTS: Randomization of 2838 persons (909 women) into CARDS was completed in June 2001. At entry, mean age was 62 years, 12% were over 70 years old and median duration of diabetes was 6 years. Median fasting lipid levels were total cholesterol 5.4 mmol/l, LDL-cholesterol 3.1 mmol/l, HDL-cholesterol 1.4 mmol/l and triglyceride 1.7 mmol/l. There was a documented history of retinopathy in 30% of patients, micro/macroalbuminuria in 11% (additionally 17% had micro/macroalbuminuria based on two elevated pretreatment measurements of albumin-creatinine ratios), hypertension in 79% and 23% were current smokers. CONCLUSION: CARDS will contribute importantly to the evidence for the macrovascular and microvascular benefits of lipid lowering with atorvastatin in patients with Type 2 diabetes. The results are likely to have important implications for the management of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text